KCM
PTGX icon

Kennedy Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Kennedy Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4M Sell
134,019
-3,080
-2% -$322K 0.29% 106
2026
Q1 		$14.5M Sell
137,099
-84,345
-38% -$7.47M 0.31% 108
2025
Q4 		$19.3M Buy
221,444
+13,007
+6% +$1.06M 0.41% 68
2025
Q3 		$13.8M Buy
208,437
+73,547
+55% +$4.18M 0.31% 110
2025
Q2 		$7.46M Sell
134,890
-2,614
-2% -$125K 0.18% 209
2025
Q1 		$6.65M Sell
137,504
-184,022
-57% -$7.71M 0.16% 219
2024
Q4 		$12.4M Buy
321,526
+54,493
+20% +$2.38M 0.28% 99
2024
Q3 		$12M Sell
267,033
-23,049
-8% -$931K 0.27% 100
2024
Q2 		$10.1M Sell
290,082
-7,986
-3% -$234K 0.21% 153
2024
Q1 		$8.62M Sell
298,068
-6,722
-2% -$183K 0.18% 205
2023
Q4 		$6.99M Sell
304,790
-14,744
-5% -$258K 0.15% 241
2023
Q3 		$5.33M Sell
319,534
-84,114
-21% -$1.63M 0.13% 274
2023
Q2 		$11.1M Buy
403,648
+72,366
+22% +$1.81M 0.26% 120
2023
Q1 		$7.62M Sell
331,282
-18,851
-5% -$317K 0.22% 156
2022
Q4 		$3.82M Buy
350,133
+251,046
+253% +$2.12M 0.11% 319
2022
Q3 		$835K Sell
99,087
-89
-0.1% -$842 0.02% 505
2022
Q2 		$784K Buy
99,176
+1,911
+2% +$23.1K 0.02% 503
2022
Q1 		$2.3M Sell
97,265
-8,129
-8% -$229K 0.05% 425
2021
Q4 		$3.6M Sell
105,394
-6,871
-6% -$217K 0.08% 392
2021
Q3 		$1.99M Buy
112,265
+40,318
+56% +$1.72M 0.04% 477
2021
Q2 		$3.23M Sell
71,947
-3,571
-5% -$118K 0.07% 433
2021
Q1 		$1.96M Buy
+75,518
New +$1.91M 0.04% 517

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kennedy Capital Management's PTGX Position: Q2 2026 in Review

Kennedy Capital Management reduced its Protagonist Therapeutics (PTGX) stake by 2.2% in Q2 2026, selling an estimated $322K and leaving 134,019 shares worth $16.4M. The position accounts for 0.29% of the portfolio, ranked #106.

Kennedy Capital Management first reported a position in PTGX in Q1 2021 and has held it in 22 quarters since. The position peaked at $19.3M in Q4 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Kennedy Capital Management held 134,019 shares of Protagonist Therapeutics worth $16.4M as of Q2 2026.
  • Kennedy Capital Management sold 3,080 Protagonist Therapeutics shares in Q2 2026, an estimated $322K.
  • Protagonist Therapeutics made up 0.29% of Kennedy Capital Management's portfolio in Q2 2026, its #106 holding.
  • Kennedy Capital Management first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Kennedy Capital Management's Protagonist Therapeutics position peaked at $19.3M in Q4 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.